Skip to main content

Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation

Buy Article:

$43.00 plus tax (Refund Policy)

Abstract Background

Previous research has shown that smokers have reduced brain and platelet monoamine oxidase B (MAOB) activity. This is probably due to some components of tobacco smoke. When smokers quit, MAOB activity returns to normal. Reduced MAO activity may increase nicotine's addictive potential. Aims

To assess whether lazabemide, a reversible selective MAOB inhibitor, promotes smoking cessation. Study design

Double-blind, randomized, placebo-controlled, multicenter phase II study. Placebo, lazabemide 100 mg/day and 200 mg/day were administered for 8 weeks. This was a dose finding, proof-of-concept, exploratory study. Setting

General practices and anti-smoking clinics in France and Belgium. Participants

Smokers smoking ≥15 cigarettes per day and motivated to quit. Main outcome measure

Sustained abstinence during the last 4 weeks of the study. Findings

The study was discontinued prematurely by the sponsor before randomization of the planned 420 smokers because of liver toxicity observed in other indications. Data of 330 randomized subjects could be analysed. Sustained abstinence during the last 4 weeks of treatment was 9%, 11% and 17% in the intent-to-treat population [P for trend: 0.036 (one-sided)]; 11%, 14% and 21% in the intent-to-treat population of smokers without those excluded because of discontinuation of the study [n = 262, P for trend: 0.02 (one-sided)], and 19%, 27% and 35% in completers [P for trend: 0.03 (one-sided)], in the placebo, lazabemide 100 mg/day and lazabemide 200 mg/day groups, respectively. Point prevalence abstinence (intent-to-treat population) at the end of treatment (week 8) was 17%, 19% and 30% in the placebo, lazabemide 100 mg/day and lazabemide 200 mg/day groups, respectively (placebo vs. lazabemide 200 mg/day: P = 0.01, one-sided). No treatment emergent major adverse event occurred. More nausea and insomnia were reported with lazabemide than with placebo. Conclusions

MAOB inhibitors are promising treatments as an aid in smoking cessation. There may be an interest to develop MAOB inhibitors with an acceptable toxicity profile. Further studies may associate MAOB inhibitors with nicotine replacement therapies to increase therapeutic efficacy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Monoamine oxidase B inhibitor; placebo-controlled; randomized study; smoking cessation

Document Type: Research Article

Affiliations: 1: Département de Pharmacologie, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Paris, France 2: Hôpital Emile Roux, Limeil-Brévannes, France, 3: F. Hoffman-La Roche, Basle, Switzerland, 4: Sylia-Stat, Antony, France, 5: and Hôpital Albert Chenevier, Créteil, France5

Publication date: 2002-10-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more